Growth hormone in inflammatory bowel disease

Alfredo Pontecorvi, Antonio Gasbarrini, Barbara De Pascalis, Maria Antonia Satta, Andrea Lupascu, Maria Chiara Mentella, Diego Leo, Paolo Pola, Domenico Melina, Laura De Marinis Grasso, Alessandro Armuzzi, 33183, DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA', ROMA - Dipartimento di Medicina e chirurgia traslazionale, A Bianchi, F Fiore, Paolo Fedeli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)


Crohn's disease and ulcerative colitis are inflammatory diseases of the gastrointestinal tract characterized by chronic relapsing inflammation and catabolism. Growth hormone/insulin-like growth factor-I axis is important in inflammatory bowel disease, because of the effects on epithelial cell kinetics, collagen deposition and immunomodulation. The potential of growth hormone as a therapeutic option in inflammatory bowel disease has been proven in various clinical settings. Acquired growth hormone resistance in inflammatory bowel disease seems to be mediated by a combination of undernutrition and active inflammation. In particular, proinflammatory cytokines, such as TNF-a and interleukin-6, have been implicated as potential mediators of growth hormone resistance. The introduction of anti-TNF-alpha monoclonal antibodies has proven very efficacious in patients with inflammatory bowel disease. By reducing cytokines levels in inflammatory cells of intestinal mucosa, infliximab could interfere with cytokine-induced growth hormone resistance. Recent in vivo data have shown that acquired growth hormone resistance in patients with inflammatory bowel disease may be reversed after the administration of anti-TNF-alpha therapy.
Lingua originaleEnglish
pagine (da-a)6-13
Numero di pagine8
RivistaEuropean Review for Medical and Pharmacological Sciences
Stato di pubblicazionePubblicato - 2006


  • IBD


Entra nei temi di ricerca di 'Growth hormone in inflammatory bowel disease'. Insieme formano una fingerprint unica.

Cita questo